Fu, X., Jin, L., Ma, P., Fan, Z
Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
The paraffin sections were counterstained with hematoxylin, dehydrated, cleared, and mounted with neutral resin (Absin Biotech, Shanghai, China
Semaglutide is a main ingredient in Type 2 diabetes treatment, and it is also effective in weight loss programs to complement increased physical activity and an improved diet
